en · de · es · fr · pt
sr9009-notes.peptides6155.com › Guide › Background And Mechanism — Reference Sheet

Background And Mechanism — Reference Sheet

By Editorial Desk · published 2026-07-28 · last reviewed 2026-08-01 · Guide

Everything below concerns freeze-thaw. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Related pages on this site

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Notes from published material

The extent to which the findings of a clinical trial can be reliably extrapolated from the subjects who participated in the trial to a broader patient population and a broader range of clinical settings. (ICH E9) Global assessment variable

==== pVII and pIX ==== In an experiment in 1995, display of Glutathione S-transferase was attempted on both pVII and pIX and failed. However, phage display of this protein was completed successfully after the addition of a periplasmic signal sequence (pelB or ompA) on the N-terminus. In a recent study, it has been shown that AviTag, FLAG and His could be displayed on pVII without the need of a signal sequence. Then the expression of single chain Fv's (scFv), and single chain T cell receptors (scTCR) were expressed both with and without the signal sequence. PelB (an amino acid signal sequence that targets the protein to the periplasm where a signal peptidase then cleaves off PelB) improved the phage display level when compared to pVII and pIX fusions without the signal sequence. However, this led to the incorporation of more helper phage genomes rather than phagemid genomes. In all cases, phage display levels were lower than using pIII fusion. However, lower display might be more favorable for the selection of binders due to lower display being closer to true monovalent display. In five out of six occasions, pVII and pIX fusions without pelB was more efficient than pIII fusions in affinity selection assays. The paper even goes on to state that pVII and pIX display platforms may outperform pIII in the long run. The use of pVII and pIX instead of pIII might also be an advantage because virion rescue may be undertaken without breaking the virion-antigen bond if the pIII used is wild type. Instead, one could cleave in a section between the bead and the antigen to elute.

Ion exchange can also be used to remove hardness from water by exchanging calcium and magnesium ions for sodium ions in an ion-exchange column. Liquid-phase (aqueous) ion-exchange desalination has been demonstrated. In this technique anions and cations in salt water are exchanged for carbonate anions and calcium cations respectively using electrophoresis. Calcium and carbonate ions then react to form calcium carbonate, which then precipitates, leaving behind fresh water. The desalination occurs at ambient temperature and pressure and requires no membranes or solid ion exchangers. The theoretical energy efficiency of this method is on par with electrodialysis and reverse osmosis.

Sources: en.wikipedia.org

Further detail

VR-1065 is a serotonin 5-HT2C receptor agonist which was under development for the treatment of obesity but was never marketed. Its pharmacology has not been described. The drug was under development by Roche and Vernalis Group. It reached phase 1 clinical trials prior to the discontinuation of its development in 2002. The drug's development was discontinued due to suboptimal pharmacokinetics in phase 1 trials. The chemical structure of VR-1065 has not been disclosed.

Honey is 17% water and 82% carbohydrates, and has negligible content of dietary fiber and protein, while containing no fat (table). Honey supplies no micronutrients in significant content (table). In a reference amount of 100 g (3.5 oz), honey supplies 300 calories.

The presence of blood in semen or hematospermia may be undetectable (it can only be seen microscopically) or visible in the fluid. Its cause could be the result of inflammation, infection, blockage, or injury of the male reproductive tract or a problem within the urethra, testicles, epididymis or prostate. It usually clears up without treatment, or with antibiotics, but if persistent further semen analysis and other urogenital system tests might be needed to find out the cause.

== Evaluation of the quality of QSAR models == QSAR modeling produces predictive models derived from application of statistical tools correlating biological activity (including desirable therapeutic effect and undesirable side effects) or physico-chemical properties in QSPR models of chemicals (drugs/toxicants/environmental pollutants) with descriptors representative of molecular structure or properties. QSARs are being applied in many disciplines, for example: risk assessment, toxicity prediction, and regulatory decisions in addition to drug discovery and lead optimization. Obtaining a good quality QSAR model depends on many factors, such as the quality of input data, the choice of descriptors and statistical methods for modeling and for validation. Any QSAR modeling should ultimately lead to statistically robust and predictive models capable of making accurate and reliable predictions of the modeled response of new compounds. For validation of QSAR models, usually various strategies are adopted:

Sources: en.wikipedia.org

Supporting material

Protein precipitation Liquid–liquid extraction Solid phase extraction Bioanalytical laboratories often deal with large numbers of samples, for example resulting from clinical trials. As such, automated sample preparation methods and liquid-handling robots are commonly employed to increase efficiency and reduce costs.

Lemonhead is an American brand of candy that was first introduced in 1962 and is produced by the Ferrara Candy Company. Lemonheads are a round, lemon flavored candy consisting of a sweet coating, a soft, sour shell, and a hard candy core. Inspiration for the Lemonhead name came from Salvatore Ferrara seeing his grandson, Salvatore II, after delivery. Salvatore II was a forceps baby and he noted that his new grandson's head was lemon shaped. The candy was born out of the same cold panned process as the company's Red Hots in 1962. In this process, layer after layer of sugar and flavor are added until the candy reaches the desired shape and size. They are most commonly sold in their standard 1 centimeter size, but they are also produced in a single-sale 3 cm version. Lemonhead candies are gluten and fat-free. Ferrara now makes 500 million Lemonheads per year. Some time between the 1980s and late 1990s, Ferrara Pan brought all of their fruit flavored candies under a consistent naming convention: Lemonheads, Grapeheads (formerly Alexander the Grape), Cherryheads (formerly Cherry Chan/Cherry Clan) and Appleheads (formerly Johnny Apple Treats). Today, only the standard Lemonhead variety remains.

The Tandem t:slim X2 insulin pump, made by Tandem Diabetes, can be integrated with the Dexcom G6 or Dexcom G7 Continuous Glucose Monitoring Systems to automate glucose regulation. Using real-time glucose data from the CGM, the t:slim X2 uses an algorithm to adjust insulin delivery based on these readings, helping to prevent glucose highs and lows. This integration enables more flexible management of blood sugar levels throughout the day. The t:slim X2 uses two predictive technologies when connected to the Dexcom CGM: Control-IQ and Basal-IQ. Control-IQ is a hybrid closed-loop system that predicts glucose levels up to 30 minutes in advance using Dexcom CGM data. It adjusts basal insulin delivery by increasing, decreasing, or halting insulin delivery as needed to maintain glucose levels within a target range. Additionally, Control-IQ can automatically administer up to one correction bolus per hour if glucose levels are expected to rise. Basal-IQ also uses Dexcom G6 data to predict glucose trends but primarily focuses on preventing lows. It stops insulin delivery if glucose is expected to drop below 4.4 mmol/L (72 mg/dL) and resumes delivery once glucose levels rise. However, Basal-IQ does not administer correction boluses or adjust insulin for elevated glucose levels.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

Network